Preclinical News and Research

RSS

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Amylin Pharmaceuticals, Inc. today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation.

20 Oct 2009

Encorium Group raises $1.6 million through private placement

Encorium Group, Inc., a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced that it has completed a private placement of 3,937,500 shares of its common stock with a private investor for an aggregate purchase price of $1,575,000, or $.40 per share.

19 Oct 2009

Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout

Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.

19 Oct 2009

Viriom picks ChemDiv's Russian subsidiary for development of innovative HIV compounds

ChemDiv, Inc. of San Diego has proudly announced that its wholly owned subsidiary Chemical Diversity Research Institute (CDRI ) of Moscow, Russia, has been chosen by Viriom Ltd. ( Viriom) of Moscow, Russia as a service partner in developing innovative HIV compounds. The program includes pre-clinical and clinical studies, which are expected to begin in 2010.

19 Oct 2009

Lubricin injections can reduce cartilage degeneration

Medical researchers will report findings today (Oct. 19) that demonstrate that injecting the protein lubricin into knee joints can dramatically reduce cartilage degeneration.

19 Oct 2009

NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference

NanoBio Corporation today announced compelling preclinical data for NB-401, a nebulized nanoemulsion-based agent that kills highly drug-resistant strains of bacteria commonly found in cystic fibrosis patients. Currently there are limited treatment options available that effectively address these resistant bacteria. The study results are being presented today at the 2009 Annual North American Cystic Fibrosis Conference (NACFC) in Minneapolis, Minn.

19 Oct 2009

Preclinical data of carfilzomib and PR-957 inhibitors to be presented at 2009 ACR/ARHP meeting

Proteolix, Inc. today announced that data from preclinical studies of carfilzomib and PR-957 will be presented at the 2009 ACR/ARHP Annual Scientific Meeting on October 16 - 21 in Philadelphia, PA.

19 Oct 2009

Research study on epileptic seizures in individuals with alcohol withdrawal syndrome

Epileptic seizures are the most dramatic and prominent aspect of the "alcohol withdrawal syndrome" that occurs when a person abruptly stops a long-term or chronic drinking habit. Researchers have shown that the flow of calcium ions into brain cells via voltage-gated calcium channels plays an important role in the generation of alcohol withdrawal seizures, because blocking this flow suppresses these seizures.

19 Oct 2009

Multi-million dollar cooperative agreement for SMA drug development program

Paratek Pharmaceuticals (Boston, MA) and Families of Spinal Muscular Atrophy (Elk Grove Village, IL) announced today that a jointly funded drug development program for Spinal Muscular Atrophy (SMA) has been awarded a multi-million dollar cooperative agreement from the National Institute of Neurological Disorders and Stroke (NINDS).

19 Oct 2009

Northern Light partners with EBSCO Publishing to provide bio-pharma and health sciences news

Northern Light (www.northernlight.com) today announced a partnership with EBSCO Publishing (EBSCO) (www.ebscohost.com) that will let mutual customers directly search and access more than 4,000 bio-pharmaceutical, health sciences and general business magazines, journals and other news sources through Northern Light SinglePoint(TM) strategic research portals.

15 Oct 2009

PEAK Surgical's PRECISE clinical study results presented at the 95th ACS Congress

PEAK Surgical, Inc. today announced results from the first of its PRECISE Clinical Studies (Pulsed Plasma Radiofrequency Energy to ReduCe Thermal Injury and Improve Surgical HEaling) demonstrating that its PEAK PlasmaBlade® tissue dissection device is associated with significant improvements in post-operative wound drainage, narcotic consumption, thermal injury, wound strength and return to normal diet volume compared with the standard of care.

15 Oct 2009

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

Critical Pharmaceuticals to develop hGH nasal spray

Critical Pharmaceuticals, the speciality pharmaceuticals company, today announced that it had secured a £1.5m translation award from the Wellcome Trust to develop a nasal spray of Human Growth Hormone (hGH) using its proprietary CriticalSorb technology as an alternative to injection.

15 Oct 2009

Commonwealth Biotechnologies to acquire GL Biochem

Commonwealth Biotechnologies, Inc. has recently announced a definitive share purchase agreement to acquire Shanghai-based GL Biochem and associated businesses (the “GL Group”), the largest global supplier of research-grade peptide products and peptide reagents.

15 Oct 2009

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.

14 Oct 2009

Roche and Genentech to discuss their radical collaborative business model at the Windhover Conference

Elsevier Business Intelligence and Windhover Conferences have announced a major addition to the lineup for their upcoming Therapeutic Area Partnerships event, Nov. 17-19 in Boston, MA. In Roche and Genentech: Understanding Their Collaborative Business Development Model, the two executives who designed and implemented the radical new collaborative business model will share exactly how they make this relationship work and the outlook for the business model in the future.

14 Oct 2009

New non-invasive technology to measure glucose levels in the human eye

New non-invasive technology designed to painlessly measure glucose levels in the human eye shows promise of one day replacing the finger-stick blood test, according to results of a pre-clinical study funded by Freedom Meditech, Inc.

14 Oct 2009

Breakthrough in pancreatic cancer treatment

Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer.

14 Oct 2009

Inovio Biomedical's proprietary DNA vaccine development platform introduced

Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, president and CEO, presented at the invitation-only World Knowledge Forum being held in Seoul, South Korea.

14 Oct 2009

Champions Biotechnology receives U.S. patent for its tubulin inhibitors

Champions Biotechnology, Inc., a drug development company with a preclinical platform able to predict clinical effectiveness, accelerate development and enhance the value of oncology drugs, today announced that the United States Patent and Trademark Office issued a patent on September 29, 2009 for the company's tubulin inhibitors, including its lead compound SG410.

14 Oct 2009

Preclinical News and Research

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Encorium Group raises $1.6 million through private placement

Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout

Viriom picks ChemDiv's Russian subsidiary for development of innovative HIV compounds

Lubricin injections can reduce cartilage degeneration

NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference

Preclinical data of carfilzomib and PR-957 inhibitors to be presented at 2009 ACR/ARHP meeting

Research study on epileptic seizures in individuals with alcohol withdrawal syndrome

Multi-million dollar cooperative agreement for SMA drug development program

Northern Light partners with EBSCO Publishing to provide bio-pharma and health sciences news

PEAK Surgical's PRECISE clinical study results presented at the 95th ACS Congress

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Critical Pharmaceuticals to develop hGH nasal spray

Commonwealth Biotechnologies to acquire GL Biochem

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

Roche and Genentech to discuss their radical collaborative business model at the Windhover Conference

New non-invasive technology to measure glucose levels in the human eye

Breakthrough in pancreatic cancer treatment

Inovio Biomedical's proprietary DNA vaccine development platform introduced

Champions Biotechnology receives U.S. patent for its tubulin inhibitors

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News